Current status and molecular biology of human papillomavirus‐independent gastric‐type adenocarcinoma of the cervix

Abstract This article reviews the findings of clinical studies on gastric‐type adenocarcinoma of the cervix to date, outline the molecular biological features identified in recent studies, and discusses the future therapeutic strategies. Gastric‐type adenocarcinoma of the cervix is a new classification in the World Health Organization 2014 classification. The World Health Organization 2020 classification further divides cervical tumors into two categories: human papillomavirus‐associated and human papillomavirus‐independent. Thus, gastric‐type adenocarcinoma of the cervix is now classified as a human papillomavirus‐independent gastric type. Clinical studies have reported that gastric adenocarcinoma of the cervix is refractory to conventional chemotherapy and radiotherapy, and it is desirable to elucidate its molecular biological mechanism. A series of gene mutations characteristic to the gastric‐type adenocarcinoma of the cervix encourage the development of future treatment strategies.